Publicado en

The objective of these guidelines from the World Health Organization (WHO) is to provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings.

WHO guidelines on second-and third-line medicines and type of insulin for blood glucose control in diabetes

en

World Health Organization, 2018

The objective of these guidelines from the World Health Organization (WHO) is to provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings.

The guidelines update the WHO Package of Essential Non-communicable Disease Interventions (WHO PEN) for primary care in low-resources settings recommendations for managing hyperglycaemia, reviewing several newer oral agents: dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) and thiazolidinediones (TZDs). The guidelines also present new recommendations on the selection of type of insulin for adults with type 1 diabetes and in adults with type 2 diabetes.

Related to point-of-care testing, the guide provides useful information related to patient preferences for reducing numbers of injections and resource requirements for different medicines related to increased needles and self-monitoring, for example.

The full publication can be accessed here.

© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. COL-08890 10/2021

Noticias relacionadas

Cards